COLLEGIUM PHARMACEUTICAL, INC. — Department of Health and Human Services SBIR Phase I: DESCRIPTION: The overall objective of the research is to further the development of an abu
COLLEGIUM PHARMACEUTICAL, INC. — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $472,811
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- DA14-013
- NAICS
- —
- Place of performance
- MA
- Period
- —
Description
DESCRIPTION: The overall objective of the research is to further the development of an abuse-deterrent formulation of the potent opioid analgesic oxymorphone utilizing the DETERx(R) platform technology. The DETERx technology is a patented formulation approach to abuse-deterrence that establishes physical and chemical barriers designed to avoid dose dumping when the formulation is subjected to a variety of common tampering techniques. The extended-release (ER) DETERx capsules contain microspheres that aredifficult to crush due to their small size and physical properties (microspheres are waxy and tend to fuse upon crushing), thereby preserving the ER characteristics following attempts at physical manipulation. Within the microspheres, the active opioid ismolecularly distributed as a hydrophobic complex in a waxy matrix, providing protection from rapid extraction in a variety of solvents even after physical manipulation. The unique microsphere formulation approach has been applied by Collegium Pharmaceutica